CTLA4 and cancer: The use of anti-programmed death-ligand 1 (anti-PD-L1), programmed death-1 (anti-PD-1) and cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) has been shown to increase life expectancy in patients with certain cancers.